When patients with advanced RET-rearranged lung cancers who received immunotherapy (n = 16) were compared with those who did not receive immunotherapy (n = 46), there was no difference in OS (hazard ratio, 1.4 [95% CI, 0.7 to 2.9]; log-rank P = .35; Appendix Fig A1). This evidence concerns the gene RET and lung carcinoma.